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Background: 
A pleural effusion refers to an accumulation of fluid in the pleural cavity between the visceral and 
parietal pleurae that occurs as a result of an imbalance between the formation and absorption of fluid 
by the pleura. This imbalance could be secondary to an alteration in the pleural surface and vascular 
permeability or due to a change in the hydrostatic pressures. Causes of pleural effusions vary from 
pleuro-parenchymal pathologies to more generalised systemic causes and organ dysfunction(Maskell 
and British Thoracic Society Pleural Disease Guideline, 2010).   
A diagnostic thoracentesis is an easy and relatively safe procedure in experienced hands, with the use 
of thoracic ultrasound. Determining the cause of an effusion is greatly facilitated by the analysis of the 
offending pleural fluid.  
In this article we look at what biochemical tests, specific biomarkers and other characteristics of 
pleural fluid that can be employed to investigate the cause of an effusion.    
 
Appearance: 
The appearance of fluid in itself can provide important information as to the aetiology of the effusion 
as shown in table 1. Straw coloured fluid could be secondary to either a transudative or an exudative 
effusion. Red or orange discolouration of the fluid is usually due to presence of blood in the fluid.  
Appearance of fluid Possible cause of the effusion 
Grossly bloody Haemothorax (check haematocrit to confirm haemothorax*) 
Creamy Empyema, chylothorax 
Black Infections such as Aspergillus niger or Rhizopus oryzae. Metastatic 
melanoma  
Chocolate coloured Amoebiasis or hepato-pleural fistula 
Offensive smell Anaerobic infection 
Presence of food 
particles 
Ruptured oesophagus 
Table 1  
* Consider haemothorax if pleural fluid haematocrit is ≥ to 50% of peripheral blood haematocrit 
 
Transudate and exudates 
Traditionally pleural effusions have been classified as transudates or exudates using Light’s criteria 
(Table 2), according to the pleural fluid protein and LDH content in comparison to serum protein and 
  
LDH(Light, 2013). This differentiation provides important information as causes of transudates are far 
fewer compared to exudates and rigorous further investigations can be avoided in most transudative 
effusions. 
Light’s Criteria  
 
Pleural fluid protein divided by serum protein  > 0.5 
 
Pleural fluid LDH divided by serum LDH > 0.6 
 
Pleural fluid LDH is more than two thirds the upper limit of normal serum LDH 
 
Table 2  
The effusion is an exudate if one or more of the above criteria are met.  A transudate would not meet 
any of the criteria.  
Using Light’s criteria 99% of the exudates can be identified correctly. However, the same criteria when 
applied to transudates has a lower sensitivity, in one series mislabelling 25% of the transudates as 
exudates (Porcel, 2011a). This was particularly common in patients with cardiac failure who were 
treated with diuretics (Porcel, 2011a).  
Transudates are formed due to systemic factors affecting oncotic and hydrostatic pressures. The 
pleural surface and capillary permeability tend to be normal in transudative processes. In contrast, 
exudative effusions are due to alteration of the pleural surface and vascular permeability in the areas 
where the fluid is produced and inefficient lymphatic drainage of absorbed fluid, which leads to the 
accumulation of fluid.  
Causes of transudates/exudates: 
Exudates 
 
Transudates 
Common causes: 
- Malignancy 
- Parapneumonic effusions 
- Tuberculosis 
Common causes 
- Left ventricular failure 
- Liver failure 
Less common causes 
- Pulmonary embolus 
- Rheumatoid arthritis and other 
autoimmune pleuritis 
- Benign asbestos effusion 
- Pancreatitis 
- Post myocardial infarction 
- Post coronary artery bypass graft 
surgery 
Less common causes 
- Hypoalbuminaemia 
- Peritoneal dialysis 
- Hypothyroidism 
- Nephrotic syndrome 
- Mitral stenosis 
Rare causes 
- Yellow nail syndrome (and other 
lymphatic disorders) 
- Drugs 
- Fungal infections 
Rare causes 
- Constrictive pericarditis 
- Urinothorax 
- Meig’s syndrome 
  
Table 3 
Pleural fluid pH: 
Pleural fluid pH is an important parameter that could influence management in patients with pleural 
infection. Normal pleural fluid pH measures approximately 7.6.  A low pleural fluid pH is secondary to 
increased metabolic activity in the pleural fluid and is often seen in conditions such as pleural 
infection, rheumatoid associated effusions and advanced malignancy.  
An effusion with a pleural fluid pH of < 7.2 in the context of clinically suspected pleural infection is 
considered to be a ‘complicated’ parapneumonic effusion, often necessitating invasive management 
of the effusion with tube drainage (Light et al., 1973, Hooper et al., 2010). 
A low pH of < 7.3 in the context of pleural malignancy is associated with a worse prognosis (less than 
30 day prognosis) and less success with chemical pleurodesis of the pleural space (2).  
A very low pH of < 7.0 is rare and is found in empyema, collagen vascular disease and oesophageal 
perforation (Good et al., 1980). 
When measuring pleural fluid pH, care should be taken to ensure pH is measured using a blood gas 
analyser or equivalent. Measurements using pH meters and strips can be inaccurate. Efforts must be 
made to ensure fluid is collected anaerobically, placed in ice and analysed within 1 hour to minimise 
alteration of the pH by external factors such as air and pCO2. Similarly Lidocaine can falsely reduce 
the pleural pH, even with volumes as small as 0.2ml (Rahman et al., 2008). Heparin was also found to 
lower pleural fluid pH.  
 
Glucose 
Pleural fluid pH and glucose are closely related reflecting their relationship with metabolic activity in 
the pleural fluid (Potts et al., 1978).  Level of glucose in the effusion is independent of the serum 
glucose level. A glucose level of < 3.4mmol/l is sufficiently low to raise concerns of conditions such as 
complicated parapneumonic effusions, rheumatoid effusions, malignancy and tuberculous effusions 
(5). Glucose measurements are less vulnerable to the effects of air, Lignocaine and delayed processing 
(Rahman et al., 2008). 
Criteria that would support a diagnosis of pleural infection    
Macroscopic appearance of pus 
Pleural fluid pH < 7.2 
Pleural fluid glucose <3.4 mmol/L  
Bacterial growth on culture 
Pleural fluid LDH >1000 IU/L 
Table 4  
The above features are not specific for pleural infection alone and should be used in conjunction with 
patient’s overall clinical condition. However, where the clinical suspicion of pleural infection is high 
and if one or more of the above criteria are met, tube drainage of the effusion should be considered, 
  
provided the collection is large enough for drainage. It is not unusual to find low glucose and an 
elevated LDH level in the pleural fluid of advanced malignant effusions (2).   
 
Other useful biochemical tests:  
Amylase/Lipase: 
Role of pleural fluid amylase is limited to conditions where the suspected underlying diagnosis is 
pancreatic disease or occasionally ruptured oesophagus (Light, 2002).  
Lipid studies: 
Cholesterol and triglyceride levels in pleural fluid are useful where an effusion is milky in appearance 
and a diagnosis of chylothorax is suspected. A triglyceride level >110mg/dl (1.24mmol/l), cholesterol 
to triglyceride level of more than 1 and a fluid to serum cholesterol level of less than 1 is considered a 
chylothorax.   
ADA 
Adenosine deaminase (ADA) is an enzyme that catalyses adenosine to inosine and is found in high 
concentration in a number of cells including lymphocytes and neutrophils. It acts as a marker of 
inflammation and is usually elevated in tuberculous pleuritis and bacterial empyema. In a low 
tuberculous incidence setting such as in the UK, a lymphocytic effusion and a raised pleural fluid ADA 
has a sensitivity of 85.7% and specificity of 98.9%, at a cut off of 35 IU/L where by it has an important 
potential role as a rule out test(Arnold et al., 2015).    
NT-proBNP 
Natriuretic hormones are neurohormones secreted by the cardiac myocytes in response to increased 
pressure and stretch of the cardiac chambers. The N-terminal of the pro-brain natriuretic peptide (NT-
proBNP) is an easily measureable marker in both serum and pleural fluid. As the pleural fluid NT-
proBNP level is adequately reflected in the serum there is no additional value in performing routine 
pleural fluid NT-proBNP.   
At a cut-off value of 1300pg/ml pleural fluid NT-pro-BNP has a sensitivity of 93% and a specificity of 
89.9% (Porcel, 2011b).  The authors find this a useful test in excluding heart failure as a cause of an 
undiagnosed unilateral effusion if the NT-ProBNP is normal, but would exercise caution in concluding 
that a raised level denotes cardiac disease as the only cause for the unilateral effusion, due to the high 
level of concurrent occult heart disease in this patient population where the average age at 
presentation is sixth or seventh decade of life. 
CRP and Procalcitonin 
Both pleural fluid C-reactive protein (CRP) and Procalcitonin (PCT) have been studied at length to 
evaluate their role in the diagnostic arena of pleural effusions. Their role is somewhat limited as these 
markers of infection can also be raised in other conditions specifically, malignancy, thereby limiting 
their role as a diagnostic marker in infection.  
  
The level of CRP in pleural fluid in isolation has limited value, but can aid in the differentiation of 
complicated from uncomplicated pleural effusions where there is clinical evidence of systemic 
infection. Uncomplicated parapneumonic effusions may resolve with antibiotics alone without the 
necessity for tube drainage but complicated parapneumonic effusions require either tube drainage or 
surgery. Currently accepted criteria for a complicated parapneumonic effusion are; pleural fluid pH < 
7.20, pleural fluid glucose < 3.3 mmol/l or the finding of septations on thoracic ultrasound within the 
right constellation of clinical features suspicious of pleural infection. A large cohort study has shown 
a pleural fluid CRP > 100 mg/l is as effective as the above measures when correctly identifying 
complicated parapneumonic effusions (Porcel et al., 2012). Furthermore if the effusion is neutrophilic, 
a much lower CRP of 45mg/l or more can identify complicated parapneumonic effusions quite reliably 
(12).   
Measuring pleural fluid PCT adds no further information and several studies have shown mixed and 
conflicting results as to the utility of pleural fluid Procalcitonin in addition to other inflammatory 
markers as mentioned above. (Porcel et al., 2012, Zou et al., 2012, Lee et al., 2013)   
Other tests 
Cell differentials: 
Cytological analysis of the pleural fluid can sometimes yield a definitive diagnosis where the malignant 
cells are easily identified from the pleural fluid. Even if no malignant cells are seen, the differential cell 
count of the pleural fluid can point towards the aetiology of the effusion. The differential cell count 
reflects the percentage composite of cells in the fluid, for example neutrophils, eosinophils, 
lymphocytes, mesothelial cells and macrophages. The type of the predominant cells can narrow the 
differential causes of the effusion as certain types of cells tend to be more prominent in certain 
diseases.  
Neutrophils: commonly effusions that are due to an underlying inflammatory pathology such as 
pneumonia, pancreatitis, sub-phrenic abscesses, pulmonary emboli and early tuberculosis.  
Eosinophils: if eosinophils make up > 10% of the cells in the fluid, the effusion is termed eosinophilic. 
These are rare, approximately 7% of all effusions are eosinophilic and most often the eosinophilia is 
secondary to the presence of air or blood in the pleural space. Other rarer causes include benign 
asbestos related pleural effusions (BAPE), Churg-Strauss disease, eosinophilic pneumonia, drugs and 
parasitic disease (Light, 2013).  
Lymphocytes: Small lymphocytes are often found in chronic effusions. Commonest causes for 
lymphocytic effusions are malignancy, post coronary artery by-pass graft (CABG) surgery and 
tuberculous pleuritis. Where an effusion is lymphocytic but the first cytology sample is negative for 
malignancy, lymphocyte subset analysis at the time of the second cytology sample may help to exclude 
a haematological malignancy. (Dixon, 2015)  
Mesothelial cells: these cells line the pleural cavity and can become dislodged at times where they 
are found in the pleural fluid. Any condition that coats the pleura such as fibrosis of the pleura 
following a sclerosing agent (as in pleurodesis) or significant inflammation of the pleural surface in 
conditions such as pleural tuberculosis can lead to an increased number of mesothelial cells found in 
  
the pleural fluid. Generally where the pleura is not significantly affected only sparse or no mesothelial 
cells are seen on the differential cell count.  
Macrophages: are common in pleural fluid but of limited diagnostic value. Often they could be 
confused with mesothelial cells and care should be taken by the pathologist when examining these 
cells.  
Biomarkers of cancer: 
Soluble Mesothelin level  
When a pleural effusion is suspected to be of a malignant aetiology, biomarkers can play an important 
role in the diagnostic pathway. Soluble Mesothelin is a novel biomarker that can be measured in both 
serum and pleural fluid where a diagnosis of mesothelioma is suspected. The literature shows a 
correlation between mesothelioma and elevated Mesothelin levels, with an exponential relationship 
between increasing tumour burden and increasing Mesothelin levels (Creaney et al., 2011). In the 
setting where a diagnosis of mesothelioma is suspected an elevated Mesothelin level in pleural fluid 
would strongly support the diagnosis, with a sensitivity of 67% and a specificity of 98% (Creaney et al., 
2007).  
Serum Mesothelin may also have a role in disease monitoring in mesothelioma, Hooper et al (Hooper 
et al., 2015) have demonstrated a falling serum Mesothelin level during chemotherapy is associated 
with a prolonged overall survival. The exact role of serum mesothelin to the oncologist in aiding the 
decision making process when managing patients with mesothelioma, is yet to be prospectively 
validated.   
Fibulin 3 
Fibulin 3 is another serum and pleural fluid marker which has a potential role in the investigation of 
Mesothelioma. Pass et al demonstrated that Fibulin 3 levels in pleural fluid of those who had 
mesothelioma were significantly higher than those who did not have the disease. They also 
demonstrated the levels were higher with advanced stage of disease and there remains a significant 
relationship between Fibulin 3 and survival (Pass et al., 2012). Further studies on Fibulin-3 have not 
been able to replicate these results, more recently Creaney et al demonstrated Fibulin 3 to be of low 
specificity for mesothelioma where a large number of patients with benign aetiology showing elevated 
levels of Fibulin 3 (Creaney et al., 2014).   
 
Conclusion 
Pleural effusions are a relatively common pathology seen on the acute medical wards. Evaluation of 
pleural fluid with simple and rapid diagnostic tests that are routinely performed in hospital 
laboratories can inform the clinicians as to the underlying cause of the effusion and aid in the 
subsequent management pathway.  
In addition to the investigations mentioned here pleural fluid when aspirated should routinely be sent 
for microbiological tests (microscopy, culture and sensitivity), including acid-alcohol fast bacilli stain 
and culture.  
  
Cytological analysis not only provides information as to the cell differential it can at times confirm the 
aetiology of the effusion where malignant cells are easily identified from the fluid.  
5 key points: 
1. Differentiating between transudate and exudate can narrow the differential diagnoses and 
guide further investigations 
2. Where ‘pus’ is aspirated on initial aspiration proceed to tube drainage of the effusion (if 
large enough) as the patient has empyema. 
3. If the pleural fluid pH < 7.2 in the clinical context of infection, tube drainage is required (if 
effusion is large enough) as unlikely to respond to antibiotic treatment alone  
4. A low pleural fluid ADA level in the context of a lymphocytic effusion virtually excludes TB 
pleuritis as the underlying cause 
5.  Lymphocyte sub sets should be sent in patients with an undiagnosed cytology negative, 
lymphocytic effusions at the time of sending a second cytology sample.   
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